DNA-hypomethylating agent, 5'-azacytidine, induces cyclooxygenase-2 expression via the PI3-kinase/Akt and extracellular signal-regulated kinase-1/2 pathways in human HT1080 fibrosarcoma cells

Yu,Seon-Mi; Kim,Song-Ja

doi:10.3892/ijo.2015.3110

DNA-hypomethylating agent, 5'-azacytidine, induces cyclooxygenase-2 expression via the PI3-kinase/Akt and extracellular signal-regulated kinase-1/2 pathways in human HT1080 fibrosarcoma cells

Authors:
- Seon-Mi Yu
- Song-Ja Kim
View Affiliations

Affiliations: Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 182, Republic of Korea
Published online on: July 31, 2015 https://doi.org/10.3892/ijo.2015.3110
Pages: 1469-1475

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cytosine analogue 5'-azacytidine (5'-aza) induces DNA hypomethylation by inhibiting DNA methyltransferase. In clinical trials, 5'-aza is widely used in epigenetic anticancer treatments. Accumulated evidence shows that cyclooxygenase-2 (COX-2) is overexpressed in various cancers, indicating that it may play a critical role in carcinogenesis. However, few studies have been performed to explore the molecular mechanism underlying the increased COX-2 expression. Therefore, we tested the hypothesis that 5'-aza regulates COX-2 expression and prostaglandin E2 (PGE2) production. The human fibrosarcoma cell line HT1080, was treated with various concentrations of 5'-aza for different time periods. Protein expressions of COX-2, DNA (cytosine-5)-methyltransferase 1 (DNMT1), pAkt, Akt, extracellular signal-regulated kinase (ERK), and phosphorylated ERK (pERK) were determined using western blot analysis, and COX-2 mRNA expression was determined using RT-PCR. PGE2 production was evaluated using the PGE2 assay kit. The localization and expression of COX-2 were determined using immunofluorescence staining. Treatment with 5'-aza induces protein and mRNA expression of COX-2. We also observed that 5'-aza-induced COX-2 expression and PGE2 production were inhibited by S-adenosylmethionine (SAM), a methyl donor. Treatment with 5'-aza phosphorylates PI3-kinase/Akt and ERK-1/2; inhibition of these pathways by LY294002, an inhibitor of PI3-kinase/Akt, or PD98059, an inhibitor of ERK-1/2, respectively, prevents 5'-aza-induced COX-2 expression and PGE2 production. Overall, these observations indicate that the hypomethylating agent 5'-aza modulates COX-2 expression via the PI3-kinase/Akt and ERK-1/2 pathways in human HT1080 fibrosarcoma cells.

View Figures

View References

1	Papagelopoulos PJ, Galanis E, Frassica FJ, Sim FH, Larson DR and Wold LE: Primary fibrosarcoma of bone. outcome after primary surgical treatment. Clin Orthop Relat Res. 373:88–103. 2000. View Article : Google Scholar : PubMed/NCBI
2	Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
3	Szyf M: The role of DNA methyltransferase 1 in growth control. Front Biosci. 6:D599–D609. 2001. View Article : Google Scholar : PubMed/NCBI
4	Stresemann C, Bokelmann I, Mahlknecht U and Lyko F: Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 7:2998–3005. 2008. View Article : Google Scholar : PubMed/NCBI
5	Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, et al: Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol. 90:345–348. 2013. View Article : Google Scholar : PubMed/NCBI
6	Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD and Seymour JF: Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 117:2697–2702. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, et al: Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 11:3604–3608. 2005. View Article : Google Scholar : PubMed/NCBI
8	Feinberg AP, Gehrke CW, Kuo KC and Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48:1159–1161. 1988.PubMed/NCBI
9	Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I and Ben-Yehuda D: Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene. 22:7737–7749. 2003. View Article : Google Scholar : PubMed/NCBI
10	Wu KK: Cyclooxygenase 2 induction: Molecular mechanism and pathophysiologic roles. J Lab Clin Med. 128:242–245. 1996. View Article : Google Scholar : PubMed/NCBI
11	Bauer AK, Dwyer-Nield LD and Malkinson AM: High cyclo-oxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 21:543–550. 2000. View Article : Google Scholar : PubMed/NCBI
12	Nurmi JT, Puolakkainen PA and Rautonen NE: Intron 1 retaining cyclooxygenase 1 splice variant is induced by osmotic stress in human intestinal epithelial cells. Prostaglandins Leukot Essent Fatty Acids. 73:343–350. 2005. View Article : Google Scholar : PubMed/NCBI
13	Chell S, Kaidi A, Williams AC and Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta. 1766:104–119. 2006.PubMed/NCBI
14	Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 1470:M69–M78. 2000.PubMed/NCBI
15	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
16	Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 62:4903–4908. 2002.PubMed/NCBI
17	Totzke G, Schulze-Osthoff K and Janicke RU: Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 22:8021–8030. 2003. View Article : Google Scholar : PubMed/NCBI
18	Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ and Mukherjee P: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and pros-taglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 11:328–339. 2004. View Article : Google Scholar : PubMed/NCBI
19	Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a gs-axin-beta-catenin signaling axis. Science. 310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D and Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis. 21:737–745. 2005. View Article : Google Scholar : PubMed/NCBI
21	Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddit V, Chiarugi V and Masini E: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. implications for tumor angiogenesis and metastasis. Neoplasia. 3:53–61. 2001. View Article : Google Scholar : PubMed/NCBI
22	Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxy-genase-2 inhibitors. Cancer Res. 60:1306–1311. 2000.PubMed/NCBI
23	Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997. View Article : Google Scholar : PubMed/NCBI
24	Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, et al: Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol. 36:263–268. 2006. View Article : Google Scholar : PubMed/NCBI
25	Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI
26	Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI
27	Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:4997–5001. 1998.PubMed/NCBI
28	Liu XH and Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 56:5125–5127. 1996.PubMed/NCBI
29	Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA and Issa JP: Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 60:4044–4048. 2000.PubMed/NCBI
30	Huang L, Zhang KL, Li H, Chen X-Y, Kong Q-Y, Sun Y, Gao X, Guan H-W and Liu J: Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China. Hum Pathol. 37:1557–1567. 2006. View Article : Google Scholar : PubMed/NCBI
31	Ramsay RG, Ciznadija D, Vanevski M and Mantamadiotis T: Transcriptional regulation of cyclo-oxygenase expression: Three pillars of control. Int J Immunopathol Pharmacol. 16:59–67. 2003.PubMed/NCBI
32	Tanabe T and Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 68–69:95–114. 2002. View Article : Google Scholar
33	St-Germain ME, Gagnon V, Mathieu I, Parent S and Asselin E: Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol. 24:1311–1324. 2004.PubMed/NCBI
34	Takeda K, Kanekura T and Kanzaki T: Negative feedback regulation of phosphatidylinositol 3-kinase/akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells. J Dermatol. 31:516–523. 2004. View Article : Google Scholar : PubMed/NCBI
35	Detich N, Hamm S, Just G, Knox JD and Szyf M: The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: A candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem. 278:20812–20820. 2003. View Article : Google Scholar : PubMed/NCBI
36	Minghetti L, Walsh DT, Levi G and Perry VH: In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J Neuropathol Exp Neurol. 58:1184–1191. 1999. View Article : Google Scholar : PubMed/NCBI
37	Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A, Basilico C, Michieli P and Comoglio PM: Different point mutations in the met oncogene elicit distinct biological properties. FASEB J. 14:399–406. 2000.PubMed/NCBI
38	Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, Tanabe T, Inoue H, Arata J and Jetten AM: Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. role of mitogen-activated protein kinases. J Biol Chem. 274:29138–29148. 1999. View Article : Google Scholar : PubMed/NCBI
39	DuBois RN, Shao J, Tsujii M, Sheng H and Beauchamp RD: G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:733–737. 1996.PubMed/NCBI
40	Trifan OC, Smith RM, Thompson BD and Hla T: Overexpression of cyclooxygenase-2 induces cell cycle arrest. evidence for a prostaglandin-independent mechanism. J Biol Chem. 274:34141–34147. 1999. View Article : Google Scholar : PubMed/NCBI
41	Santoro MG, Philpott GW and Jaffe BM: Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature. 263:777–779. 1976. View Article : Google Scholar : PubMed/NCBI
42	Shimakura S and Boland CR: Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth. Cancer Res. 52:1744–1749. 1992.PubMed/NCBI
43	DeRubertis FR, Craven PA and Saito R: 16,16-dimethyl prostaglandin E2 suppresses the increases in the proliferative activity of rat colonic epithelium induced by indomethacin and aspirin. Gastroenterology. 89:1054–1063. 1985.PubMed/NCBI
44	Prasad KN: Morphological differentiation induced by prostaglandin in mouse neuroblastoma cells in culture. Nat New Biol. 236:49–52. 1972. View Article : Google Scholar : PubMed/NCBI
45	Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 276:18075–18081. 2001. View Article : Google Scholar : PubMed/NCBI
46	Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 8:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
47	Gweon EJ, Jung JC and Kim SJ: Luteolin induces inhibition of cell proliferation and COX-2 expression via ERK pathway in human fibrosarcoma HT1080. Cancer Prev Res (Phila). 17:218–225. 2012.
48	Rashid A and Issa JP: CpG island methylation in gastroenterologic neoplasia: A maturing field. Gastroenterology. 127:1578–1588. 2004. View Article : Google Scholar : PubMed/NCBI
49	Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ and Wilson KT: Promoter methylation regulates helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 61:2399–2403. 2001.PubMed/NCBI
50	Mercau ME, Astort F, Giordanino EF, Martinez Calejman C, Sanchez R, Caldareri L, Repetto EM, Coso OA and Cymeryng CB: Involvement of PI3K/akt and p38 MAPK in the induction of COX-2 expression by bacterial lipopolysaccharide in murine adrenocortical cells. Mol Cell Endocrinol. 384:43–51. 2014. View Article : Google Scholar : PubMed/NCBI
51	Yu SM and Kim SJ: Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/akt, p38, and JNK pathways in rabbit articular chondrocytes. Exp Cell Res. 319:2822–2834. 2013. View Article : Google Scholar : PubMed/NCBI